AVAT-041

AVAT-041 is a solid dose investigational drug being developed by Avata Biosciences for the treatment of neurological and psychiatric disorders, specifically adult focal epilepsy, pediatric focal epilepsy, schizophrenia, opioid sparing (pain management), and addiction. The company specializes in next-generation cannabinoid medicines using synthetic cannabinoids with novel formulation processes to address unmet medical needs in neurology and mental health. While the precise active ingredient or mechanism of action for AVAT-041 is not explicitly stated in public sources, Avata Biosciences’ pipeline focuses on synthetic cannabinoids beyond plant-derived cannabidiol (CBD), suggesting that AVAT-041 likely involves a proprietary synthetic cannabinoid or related compound[1].